TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2350777

Group type: EXPERIMENTAL
Intervention: Thrombolysis (group T, n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (group K, n = 18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Thrombolysis (group T)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (group K)
Number of subjects: 35
Study: 4392540

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MJ 1999
Number of subjects: 0
Study: 31954199

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) - 300 kcal
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mixed Meal Tolerance Test - 1130 kcal
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fasting P1NP
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Meal-induced suppression of P1NP
Number of subjects: 64
Study: 30659702

Group type: EXPERIMENTAL
Intervention: Weekly prompted BP self-monitoring and healthy behavior text messages
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study: 28335835

Group type: EXPERIMENTAL
Intervention: Thrombolysis with tenecteplase
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 25559659

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1,200 mg starting two days before the operation, in addition to isonitrogenous and isocaloric total parenteral nutrition.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 33
Study: 23321948

Group type: EXPERIMENTAL
Intervention: Tagged vaginal gel (4 mL of tenofovir placebo gel with 15 mg 2‐pentyl acetate)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tagged condom (with 15 mg 2‐butyl acetate)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tagged products
Number of subjects: 25
Study: 20589903

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study: 19526810

Group type: EXPERIMENTAL
Intervention: Point injection of red-sage-root (Danshen) in 5 ml normal saline, 2.5 ml per point, 3 times a week for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Core decompression (CDC) surgery
Number of subjects: 62
Study: 17937531

Group type: EXPERIMENTAL
Intervention: Initial concern severity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expression of three severe concerns immediately after trauma
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical health concerns
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Work and finance concerns
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Social concerns
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Psychological concerns
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Medical concerns
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Legal concerns
Number of subjects: 120
Study: 15133849

Group type: EXPERIMENTAL
Intervention: Hejie decoction (HJD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine Western medicine (Control)
Number of subjects: 65
Study: 11481387

Group type: EXPERIMENTAL
Intervention: Initial PSA screening (first round)
Number of subjects: 4491

Group type: EXPERIMENTAL
Intervention: Second PSA screening (four years later)
Number of subjects: 4491
Study: 9504446

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/diltiazem ER 120 mg (E5/D120)
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/diltiazem ER 180 mg (E5/D180)
Number of subjects: 891

Group type: COMPARATOR
Intervention: All active treatments
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Fixed combination of enalapril/diltiazem ER (E/D)
Number of subjects: 891
Study: 8002149

Group type: EXPERIMENTAL
Intervention: Itraconazole, 100 mg daily for 6 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Griseofulvin, 500 mg daily for 6 weeks
Number of subjects: 35
Study: 3400564

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg three times a day in 10 patients and four times a day in 9 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diltiazem (after 14 days of diltiazem alone)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Digoxin (0.125 mg/day in 2 patients and 0.250 mg/day in 17 patients)
Number of subjects: 19
Study: 31288666

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 0
Study: 28100529

Group type: COMPARATOR
Intervention: Tablet computer based interactive distraction (TAB)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg kg-1) (MDZ)
Number of subjects: 118
Study: 26423502

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide mixed with 0.2% chlorhexidine digluconate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Calcium hydroxide mixed with normal saline
Number of subjects: 55
Study: 23205717

Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fractional CO(2) laser
Number of subjects: 24
Study: 21724623

Group type: EXPERIMENTAL
Intervention: Pegnivacogin 1 mg/kg
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control agent (anivamersen)
Number of subjects: 800
Study: 19633475

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d alone (arm A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d in combination with bortezomib 1.6 mg/m2 (arm B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erlotinib +/- bortezomib in patients with epidermal growth factor receptor mutations
Number of subjects: 50
Study: 16752169

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg or 80 mg daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 215
Study: 15324925

Group type: EXPERIMENTAL
Intervention: Gamma-irradiated minitablets containing ciprofloxacin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dry heat sterilisation minitablets containing ciprofloxacin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Gamma-irradiation
Number of subjects: 7
Study: 11733128

Group type: COMPARATOR
Intervention: Non-plantar heel pain group
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Plantar heel pain group
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Coefficient b1
Number of subjects: 166

Group type: COMPARATOR
Intervention: Coefficient b0
Number of subjects: 166
Study: 9223713

Group type: EXPERIMENTAL
Intervention: Nebulized distilled water
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution (isotonic saline)
Number of subjects: 40
Study: 7963104

Group type: EXPERIMENTAL
Intervention: front‐loaded recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 382

Group type: COMPARATOR
Intervention: anistreplase (APSAC)
Number of subjects: 382

Group type: COMPARATOR
Intervention: combination thrombolytic therapy
Number of subjects: 382
Study: 3311283

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 69

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 69
Study: 30269747

Group type: EXPERIMENTAL
Intervention: Upright position, 60 mg prasugrel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position, 60 mg prasugrel
Number of subjects: 20
Study: 26518241

Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Educational-control program
Number of subjects: 28
Study: 24092406

Group type: EXPERIMENTAL
Intervention: CPB leukocyte filtration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 20
Study: 22325134

Group type: EXPERIMENTAL
Intervention: Risk Reduction (RR) program
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Risk Avoidance (RA) program
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1258
Study: 20234133

Group type: EXPERIMENTAL
Intervention: Central adjudication of clinical events
Number of subjects: 0
Study: 18608053

Group type: EXPERIMENTAL
Intervention: Intravaginal gel (microbicide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived male partner acceptance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qualitative research findings
Number of subjects: 0
Study: 15831192

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11942734

Group type: EXPERIMENTAL
Intervention: Red Orange Complex (ROC) 50 mg/d, orally
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (28 healthy volunteers)
Number of subjects: 33
Study: 10512958

Group type: EXPERIMENTAL
Intervention: Intraoral parallelometer
Number of subjects: 32

Group type: COMPARATOR
Intervention: Freehand tooth preparations
Number of subjects: 32

Group type: COMPARATOR
Intervention: Guiding pin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Extraoral parallelometer
Number of subjects: 32
Study: 7719358

Group type: EXPERIMENTAL
Intervention: Moxisylyte hydrochloride (0.5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2332986

Group type: EXPERIMENTAL
Intervention: Combination of chlorambucil and prednisolone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Prednimustine
Number of subjects: 65
Study: 204058

Group type: EXPERIMENTAL
Intervention: Gaviscon tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antacid
Number of subjects: 0
Study: 30689098

Group type: EXPERIMENTAL
Intervention: Nasal mask combined with mandibular advancement device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 0
Study: 28587616

Group type: EXPERIMENTAL
Intervention: Mirococept 10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mirococept (5-25 mg, dose allocation based on interim analysis)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard cold perfusion fluid (Soltran®)
Number of subjects: 80
Study: 26853341

Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance exercise training (EX)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Relaxation control group
Number of subjects: 103
Study: 24088295

Group type: EXPERIMENTAL
Intervention: Glaucoma screening intervention
Number of subjects: 0
Study: 22652183

Group type: EXPERIMENTAL
Intervention: Pixantrone dimaleate (85 mg/m² intravenously on days 1, 8, and 15 of a 28-day cycle, for up to six cycles)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine at prespecified standard doses and schedules)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pixantrone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 140
Study: 21092261

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 5754

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 5754
Study: 18563435

Group type: EXPERIMENTAL
Intervention: DHA (2 g/day) + EPA (3 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 12
Study: 15804658

Group type: EXPERIMENTAL
Intervention: Ototopical treatments for chronic suppurative otitis media; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-controlled research model; details on specific interventions not available.
Number of subjects: 0
Study: 11872916

Group type: EXPERIMENTAL
Intervention: Statin agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional antithrombotic agents
Number of subjects: 0
Study: 10510145

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desipramine 100 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7501537

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation combined with guided imagery
Number of subjects: 0
Study: 1384397

Group type: EXPERIMENTAL
Intervention: Hydromorphone alone by bolus administration
Number of subjects: 170

Group type: COMPARATOR
Intervention: Hydromorphone with a continuous (basal) infusion
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Hydromorphone in combination with 0.08% bupivacaine by bolus administration
Number of subjects: 170

Group type: COMPARATOR
Intervention: Hydromorphone and bupivacaine, with a concurrent infusion of both drugs
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: All four groups
Number of subjects: 170
Study: 3893680

Group type: EXPERIMENTAL
Intervention: MDF (6141 cGy/4.5 weeks/69 fractions at 89 cGy every 3‐4 hours, three times a day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MDF + Misonidazole (1.25 g/m2 three times weekly for the first 3 weeks)
Number of subjects: 124

Group type: COMPARATOR
Intervention: CF (5800 cGy/6 weeks/30 fractions)
Number of subjects: 124
Study: 31239331

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) for BAO
Number of subjects: 165
Study: 30032883

Group type: EXPERIMENTAL
Intervention: Transport in a children's ride-on toy car (Group C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Transport on a gurney without premedication (Group G)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Transport on a gurney with oral midazolam 0.5 mg kg-1 (Group M)
Number of subjects: 108
Study: 27130263

Group type: EXPERIMENTAL
Intervention: Valveless Trocar Insufflation System (VI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional Insufflation System (CI)
Number of subjects: 56
Study: 24655936

Group type: EXPERIMENTAL
Intervention: 30° head-down tilt (HDT) for 10 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Horizontal supine position (HS)
Number of subjects: 11
Study: 23683446

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 60
Study: 21399855

Group type: EXPERIMENTAL
Intervention: Stretching group (SG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 17
Study: 19526249

Group type: EXPERIMENTAL
Intervention: Praneem tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17510726

Group type: EXPERIMENTAL
Intervention: 10 mm stainless steel posts
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mm quartz‐fiber posts
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mm stainless steel posts
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mm quartz‐fiber posts
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both post systems
Number of subjects: 40
Study: 15451335

Group type: EXPERIMENTAL
Intervention: Single dose of oral misoprostol (600 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Repeated dose of oral misoprostol (1200 microg total, given as 600 microg every 4 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Repeated dose of oral misoprostol (1200 microg total)
Number of subjects: 100
Study: 11352373

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - 2 hour session
Number of subjects: 56

Group type: COMPARATOR
Intervention: Educational intervention - 2 hour COPD education
Number of subjects: 56
Study: 9671370

Group type: EXPERIMENTAL
Intervention: 5 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Number of subjects: 24
Study: 7743685

Group type: EXPERIMENTAL
Intervention: Enoximone (bolus-infusion of 0.5 mg/kg over 10 min followed by an infusion of 5 micrograms/kg/min up to 20 micrograms/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epinephrine/nitroglycerin (infusion of 0.05 and 0.5 micrograms/kg/min, respectively, for 4 hours postoperatively)
Number of subjects: 12
Study: 2201732

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg at bed time
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7282598

Group type: EXPERIMENTAL
Intervention: High plasma vitamin C levels (16.28 +/- 3.75 mg/l) due to supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low plasma vitamin C levels (6.15 +/- 3.88 mg/l)
Number of subjects: 20
Study: 31578168

Group type: EXPERIMENTAL
Intervention: Transbronchial lung cryobiopsy (TBLC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Surgical lung biopsy (SLB)
Number of subjects: 65
Study: 31796486

Group type: EXPERIMENTAL
Intervention: Home treatment (n=101)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Hospital treatment (n=102)
Number of subjects: 203
Study: 28100019

Group type: EXPERIMENTAL
Intervention: HVPG-guided therapy
Number of subjects: 170
Study: 26520144

Group type: COMPARATOR
Intervention: AC (adriamycin 60 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by docetaxel 100 mg/m(2) with primary GCSF prophylaxis
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: FEC (5‐fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) followed by docetaxel 75 mg/m(2)
Number of subjects: 148
Study: 23640486

Group type: EXPERIMENTAL
Intervention: Hypolipidemic therapy (fenofibrate, niacin, diet, and exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV/ART HDL
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV/ART plasma
Number of subjects: 0
Study: 22093195

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Separate administration of aspirin, ramipril, and simvastatin
Number of subjects: 4000
Study: 19236773

Group type: EXPERIMENTAL
Intervention: Newly diagnosed APL
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Relapsed APL
Number of subjects: 143

Group type: COMPARATOR
Intervention: HLA‐DR(‐) AML
Number of subjects: 143

Group type: COMPARATOR
Intervention: DR(‐) AML
Number of subjects: 143
Study: 17710007

Group type: EXPERIMENTAL
Intervention: Khan Kinetic Treatment (KKT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 44
Study: 16163169

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional fluorouracil, cisplatin, and radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing the dose of radiotherapy or adding a brachytherapy boost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer targeted therapies
Number of subjects: 0
Study: 11528196

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 40 mg vardenafil
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both doses of vardenafil (20 mg and 40 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9749589

Group type: EXPERIMENTAL
Intervention: Deprenyl (selegiline) 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-label deprenyl treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0
Study: 7810015

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microgrammes daily via Turbuhaler)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 37
Study: 1903317

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rTPA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 6102896

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow-release preparations of Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow-release preparations of Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penbutolol and Propranolol
Number of subjects: 0
Study: 31596983

Group type: EXPERIMENTAL
Intervention: Active air cleaners
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo air cleaners
Number of subjects: 24
Study: 30760320

Group type: EXPERIMENTAL
Intervention: Umbilical therapy with Lishui Xiaogu cataplasm plus red light irradiation along with conventional treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo cataplasm plus red light irradiation along with conventional treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 28190675

Group type: EXPERIMENTAL
Intervention: Exergaming group (EGG) (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional exercise group (CG) (n = 10)
Number of subjects: 20
Study: 26490012

Group type: EXPERIMENTAL
Intervention: mHealth program (Text4Heart) delivered via SMS and website, 24-week duration
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: mHealth program (Text4Heart)
Number of subjects: 123

Group type: COMPARATOR
Intervention: usual care (traditional CR)
Number of subjects: 123
Study: 23663658

Group type: EXPERIMENTAL
Intervention: Bosentan (endothelin receptor antagonist) administered for 14 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study: 21832027

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified milk (mean intake of 3.7 μg/d)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Red meat (control group)
Number of subjects: 181
Study: 19636983

Group type: EXPERIMENTAL
Intervention: Extended information
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study: 17346425

Group type: EXPERIMENTAL
Intervention: Reparixin (12 subjects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (8 subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 20